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http:WHAT THIS PAPER ADDS
This study adds up-to-date evidence that patients with population-based screening detected abdominal aortic
aneurysms have a very low post-operative mortality. This provides further support for existing national screening
programs and for countries that are setting up new programs. This is also important information for the vascular
surgeon informing patients that are diagnosed with an aneurysm at population-based screening.Objectives: Screening for abdominal aortic aneurysms (AAAs) substantially reduces aneurysm-related mortality in
men and is increasing worldwide. This cohort study compares post-operative mortality and complications in men
with screening-detected vs. non-screening-detected AAAs.
Methods: Data were extracted from the Swedish National Registry for Vascular Surgery (Swedvasc) for all
screening-detected men treated for AAA (n ¼ 350) and age-matched controls treated for non-screening-detected
AAA (n ¼ 350).
Results: There were no differences in baseline characteristics besides age, which was lower in the screening-
detected group than in the non-screening-detected group (median 66 vs. 68, p < .001). Open repair was used
more frequently than endovascular aortic repair (EVAR) in patients with screening-detected AAAs than in non-
screening-detected controls (56% vs. 45% p ¼ .005). No differences in major post-operative complications at 30
days were observed between the groups. In patients treated with open repair there were no differences in 30-
day, 90-day or 1-year mortality in screening-detected patients compared to non-screening-detected controls
(1.0% vs. 3.2% p ¼ .25, 2.1% vs. 4.5% p ¼ .23, 4.1% vs. 5.8% p ¼ .61). None of the patients treated with EVAR in
either group died within 30 days. The 90-day mortality after EVAR was lower in patients with screening-detected
AAA than in those with non-screening-detected AAAs (0.0% vs. 3.1%, p ¼ .04). No difference in the 1-year
mortality was detected in the EVAR-patients between the two groups (1.4% vs. 4.7%, p ¼ .12).
Conclusions: The contemporary post-operative mortality after AAA surgery was low in this national audit of
patients with screening-detected AAAs and age-matched controls. Patients with screening-detected AAAs have
the same frequency of complications at 30 days as patients with non-screening-detected AAA. This study gives
further support to national screening programs for the detection of AAA in men.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Screening for abdominal aortic aneurysm (AAA) with ultra-
sound in men substantially reduces aneurysm-related mor-
tality,1e4 and also reduces all-cause mortality.5,6 AAA
screening in Sweden started regionally in 2006 and, atof original article: http://dx.doi.org/10.1016/j.ejvs.2014.10.016
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//dx.doi.org/10.1016/j.ejvs.2014.08.024present, 95% of 65 year old men in Sweden are invited to
annual screening. In the screening programs, population-
based national registries are used for structured invitations.
The participation rate in the screening-programs ranges be-
tween 78% and 86%.7e9 All individuals with an AAA detected
in screening are referred to a vascular specialist, and are
subsequently included in an AAA imaging surveillance pro-
gram. Patients with an AAA diameter exceeding 5.5 cm are
generally evaluated for prophylactic surgery.10,11 There is no
consensus about which type of intervention (open repair
[OR] or endovascular aortic repair (EVAR)) should be the ﬁrst
line of treatment for the screening-detected patients,
although there is an ongoing debate.12e15 There are some
650 A. Linné et al.reports on the outcome of surgery on screening-detected
AAA, as well as a meta-analysis of post-operative mortality
based on randomized AAA screening-trials.2,16e19 Recent
randomized trials on non screening-detected aneurysms
have demonstrated very low post-operative mortality.20,21 A
recent British study reports low post-operative mortality for
patients aged 65 and younger.15 Hence, post-operative AAA
mortality has decreased and when discussing choice of
treatment with screening-detected patients it is important to
have a good estimate of their surgical risk, preferably well
beyond 30 days. Since most aneurysms are asymptomatic,
the diagnosis of non-screening-detected aneurysms is often
made when investigating some other disease. In theory, it is
therefore possible that screening-detected men are afﬂicted
to a lesser extent by comorbidities. In the future we will
gradually see an increasing rate of screening-detected AAA in
male patients, and men with AAA who are non-screening
detected will consist of men who have not participated in
the screening programs. Studies show that non-participants
in screening have, to a greater extent, a low level of educa-
tion, low income, and are more likely to be smokers, recent
immigrants, and have a higher frequency of stroke, diabetes,
chronic obstructive pulmonary disease, and renal fail-
ure.7,22e25 Hence, it is reasonable that, over time, the male
non-screening-detected AAA patient will present a more
demanding surgical challenge than the screening-detected
patient.Figure 1. Flowchart ofThe primary aim of this study was to compare post-
operative outcome within 30 days in patients with
screening-detected AAA versus non screening-detected AAA
in a population-based setting. Secondary aims were to
analyze mortality up to 1 year, pre-operative comorbidity,
and choice of surgical method. Our hypothesis was that
patients with screening-detected AAA have a better post-
operative outcome due to less pre-operative comorbidity.
METHODS
Study design
This was a retrospective cohort study comparing two male
cohorts: screening-detected AAAs and non-screening-
detected age-matched controls.
Setting and participants
Data were extracted from the Swedish National Registry for
Vascular Surgery (Swedvasc). Eligibility criteria were all
elective aortic repairs from May 7, 2010, to January 15,
2013, (n ¼ 2135) (Fig. 1). All women were excluded
(n ¼ 164). To exclude procedures performed for any other
indication than AAA size (iliac aneurysms, aortoiliac occlu-
sive disease), all repairs in patients with an aortic diameter
of <50 mm were excluded (n ¼ 164). A few centers screen
for AAA while the patient is being examined for other
vascular diseases, with the result that some AAA are clas-
siﬁed as screening detected without being identiﬁed bypatient selection.
Outcome after Surgery on Screening-Detected AAA’s 651population-based screening. In order to minimize this bias,
data were collected from all centers regarding age groups
offered population-based screening and these data were
matched with Swedvasc-data on the year of birth of the
patient. Patients who could not have been subject to
population-based screening were redirected to the non-
screening detected group. Patients whose screening status
was “unknown” were excluded (n ¼ 12).
When randomly selecting the 350 age-matched controls,
age matching had to allow for a span of 2 years in order to
achieve a sufﬁcient number. The screening-detected aneu-
rysms (n ¼ 350) were then compared with those of age-
matched controls with non-screening-detected aneurysms
(n ¼ 350) regarding comorbidity, choice of surgical method,
mortality, and complications after surgery. For each
screening-detected AAA, an age-matched control (within 2
years) was selected from the non-screening-detected
cohort. This matching was done to improve the efﬁciency
of the study since age is an important confounder of post-
operative mortality and the age difference between the
screening detected and all the non-screening-detected was
large (mean 68 vs. mean 74). Further matching was not
performed since it would have decreased the power even
more. The primary endpoint was deﬁned as a combined
endpoint of mortality and major adverse events, including
acute myocardial infarction (AMI), stroke, amputation,
bowel ischemia, and renal failure, within 30 days. The
combined endpoint was constructed in accordance with the
ACE trial.21,26 Secondary endpoints were differences in post-
operative mortality (30 days, 90 days, and 1 year), pre-
operative comorbidity and choice of surgical method.
Comorbidities reported in Swedvasc were deﬁned as fol-
lows: diabetes, diabetes with medical treatment; cardiac
disease, history of coronary artery disease or congestive
heart failure; hypertension, hypertension with medical
treatment; pulmonary disease, chronic obstructive pulmo-
nary disease or emphysema or other chronic pulmonary
disease with symptoms. Pre-operative renal failure was
deﬁned as a creatinine level above 150 in accordance with a
previous Swedvasc study.27 Ever smoking was deﬁned asTable 1. Clinical characteristics and pre-operative risk factors in scree
matched controls.
Clinical characteristics Screening-detected, n (%
All subjects
Age (yrs)a 66 (65e70)
Diabetes 36 (10.7)
Ever-smoker 277 (90.5)
Cardiac disease 128 (38.1)
Previous TIA/stroke 39 (11.7)
Hypertension 252 (75.0)
Creatinine > 150 mmol/L 7 (2.0)
Pulmonary disease 64 (19.2)
Maximal AAA diameter (mm)a 59 (55e64)
Note. Values in parenthesis are percentages, unless indicated otherw
attack.
a Values are median (IQR). P-values are based on the ManneWhitney t
(2-sided) for comorbidity variables and smoking.current or previous smoking. Age was categorized in two
groups to create two groups of similar size: < 68 years
(n ¼ 346) or  68 years (n ¼ 354). Limited power did not
allow for more subgroups of age. The study was approved
by the regional ethics committee in Uppsala (Dnr 2012/
282).The Swedvasc Registry
Sweden’s National Registry for Vascular Procedures, Swed-
vasc, was started in 1987 and became nationwide in 1994
and covers all centers performing AAA surgery in the
country. The Registry is fully web based and data are
collected prospectively. Surgeons register risk factors, peri-
operative data and complications at 30 days. Data on
peri-operative medication are not available. Every month
the Registry is interconnected with the Swedish Death
Registry, thereby allowing for completely accurate data
regarding mortality in all the registered patients. The Reg-
istry does not include causes of death. The Registry has
been found to have a 93.1% external validity for registration
of abdominal aortic aneurysms (AAAs).28e30 All hospitals
performing elective repairs contribute to Swedvasc but a
few ruptures may be operated on in hospitals not doing
elective repairs and some centers do not achieve 100%
registration each year.
In July 2010, a new mandatory variable requiring infor-
mation concerning whether the aneurysm was detected by
screening or not was implemented. Since this screening
variable has not been validated previously, a random sam-
ple of 100 patients was cross-matched for the variable
against medical record data from four of the population-
based screening centers.Statistics
Randomization and all statistical analyses were performed
using IBM SPSS Statistics 22.0. For two-group comparisons
Fisher’s and ManneWhitney tests were used, as appro-
priate. A p-value < .05 was considered signiﬁcant and all
tests were two-sided. Cases with missing data werening-detected patients compared to non-screening-detected age-
) Non-screening-detected
age-matched controls, n (%)
p
68 (66e72) .001
46 (12.5) .16
256 (90.8) 1.00
142 (44.7) .10
48 (15.0) .25
247 (77.7) .46
14 (4.0) .18
72 (23.0) .25
59 (55e65) .43
ise. AAA ¼ abdominal aortic aneurysm; TIA ¼ transient ischemic
est for age and maximal aneurysm diameter and Fisher’s exact test
Figure 2. Percentage of patients treated with EVAR or open repair
in Sweden. From May 2010 to January 2013. Non-screening-
detected age-matched controls compared to screening-detected
p < .01; non-screening-detected all ages compared to screening-
detected p < .001
652 A. Linné et al.excluded from corresponding analysis as noted in tables and
ﬁgures.
Binary logistic regression was used for the analysis of risk
factors possibly inﬂuencing the major adverse events at 30
days and mortality within 90 days. A univariate analysis was
performed followed by multivariate adjusted analyses.
Variables introduced “a priori” to the adjusted models were
screening status, age and surgical method (OR or EVAR). The
limited number of events did not allow for further
adjustments.RESULTS
Baseline data, comorbidity, and choice of surgical method
There were no differences in baseline characteristics or
comorbidities besides age, which was lower in the
screening-detected group than in the non-screening-
detected group (median 66 [IQR, 65e70] vs. 68 [IQR, 66e
72], p < .001 [mean age 68.0  3.5 vs. 69.1  4.1])
(Table 1). The necessary allowed age span when randomly
selecting controls (see Methods) explains the age-difference
between the groups. As shown in Fig. 2, OR was more usualTable 2. Complications 30 days after surgery in screening-detected AAA
with outcome due to missing data).
Complications 30
days after surgery
Open repair
Screening-
detected, n (%)
Non-screening-detected
age-matched controls, n (%
n ¼ 195 n ¼ 157
Death 2 (1.0) 5 (3.2)
AMI 4 (2.2) 2 (1.4)
Stroke 2 (1.1) 3 (2.0)
Amputation 0 (0) 1 (0.7)
Bowel ischemia 1 (0.5) 1 (0.7)
Renal failure 7 (3.7) 8 (5.4)
Combined endpointa 12 (6.4) 16 (10.6)
Abd compartment 6 (3.2) 6 (4.1)
Distal embolization 5 (2.7) 5 (3.4)
Reop bleeding 2 (1.1) 4 (2.7)
AAA ¼ abdominal aortic aneurysm; AMI ¼ acute myocardial infarction
a Primary (combined) endpoint. Any of the following: death, AMI, stroamong patients with screening-detected aneurysms than
among those with non-screening-detected aneurysms (56%
vs. 45%, p ¼ .01).
Complications after surgery
Overall, both groups had few post-operative complications
at 30 days, but there were more complications after open
surgery than after EVAR (Table 2). There was no difference
in complication rates between patients with screening-
detected and those with non-screening-detected aneu-
rysms when separated into OR and EVAR (Table 2). The
primary endpoint (combined endpoint: death, AMI, stroke,
amputation, bowel ischemia, renal failure) was equal in
screening-detected versus non-screening-detected cases
after OR (6.4% vs. 10.6% p ¼ .17) and after EVAR (2.0% vs.
3.8%, p ¼ .52) (Table 2). Multivariable logistic regression
(Table 3) shows no difference in risk of major adverse
events for non-screening-detected patients (OR 1.64, 95%
CI 0.82e3.25) when adjusted for age and method of
intervention (EVAR or OR). The infrequent outcome (major
adverse events at 30 days) did not allow further adjustment
for potential confounders.
Mortality after surgery
Mortality among screening-detected versus all non-
screening-detected aneurysms (all ages) are shown in
Table 4. The non-screened group with a much higher mean
age (74 vs. 68) had a higher post-operative mortality at one
year (2.9% vs. 5.7%, p ¼ .048).
Mortality at 30 days, 90 days, and 1 year is presented for
screening-detected and age-matched controls, separately
for OR versus EVAR (Table 5). At 30 days and 1 year, and in
both types of aneurysm repair, there was no difference in
mortality between the groups (Table 5). Mortality at 90
days in screening-detected patients treated with EVAR was
lower than in patients with non-screening-detected AAAs
(0% vs. 3.1%, p ¼ .04, Table 5). The 90-day mortality after
OR did not differ between screening-detected and non-
screening-detected AAAs (2.1% vs. 4.5%, p ¼ .23).patients compared to age matched controls n ¼ 663e700 (varies
EVAR
)
p Screening-
detected, n (%)
Non screening-detected
age-matched controls, n (%)
p
n ¼ 155 n ¼ 193
0.25 0 (0) 0 (0) 1.00
0.70 0 (0) 2 (1.1) 0.50
0.66 1 (0.7) 1 (0.5) 1.00
0.44 0 (0) 0 (0) 1.00
1.00 0 (0) 0 (0) 1.00
0.60 2 (1.4) 5 (2.7) 0.47
0.17 3 (2.0) 7 (3.8) 0.52
0.77 2 (1.4) 0 (0) 0.20
0.75 2 (1.4) 2 (1.1) 1.00
0.41 1 (0.7) 5 (2.7) 0.23
; EVAR ¼ endovascular aortic repair.
ke, major amputation, bowel ischemia, renal failure.
Table 3. Odds ratio (OR) for primary endpoint consisting of any of the following: death, AMI, stroke, major amputation, bowel ischemia,
renal failure within 30 days. Univariate (crude) and adjusted analyses (n ¼ 668, 32 patients excluded due to missing data).
Frequency and risk of death Primary endpoint
at 30 daysa, n (%)
OR crude
primary endpoint
CI 95% OR adjb primary
endpoint
95% CI
n ¼ 668 n ¼ 668
All 38 38
Screening-detected 15 (4.3) Ref Ref
Non-screening-detected (missing ¼ 0) 23 (6.6) 1.57 0.81e3.07 1.64 0.82e3.25
Open Repair 28 (8.0) 2.89 1.38e6.05 3.27 1.54e6.93
EVAR (missing ¼ 0) 10 (2.9) Ref Ref
Age < 68 15 (4.3) Ref 0.79e2.99 Ref 0.81e3.21
Age  68 (missing ¼ 0) 23 (6.5) 1.53 1.61
Hypertension, No 8 (5.2) Ref
Hypertension, Yes (missing ¼ 46) 28 (5.6) 1.12 0.50e2.50
Diabetes, No 32 (5.6) Ref
Diabetes, Yes (missing ¼ 43) 4 (4.9) 0.85 0.29e2.48
Creatinine < 150 35 (5.2) Ref
Creatinine > 150 (missing ¼ 0) 3 (14.3) 3.29 0.92e11.82
Ever-smoker 33 (6.2)
Never-smoker (missing ¼ 112) 0
Previous heart cond., No 12(3.1) Ref
Previous heart cond., Yes (missing ¼ 46) 24 (9.0) 3.10 1.52e6.33
Respiratory disease, No 21 (4.1) Ref
Respiratory disease, Yes (missing ¼ 54) 15 (11.1) 2.88 1.44e5.76
Previous TIA/Stroke, No 32 (5.7) Ref
Previous TIA/Stroke, Yes (missing ¼ 46) 4 (4.6) 0.80 0.28e2.32
EVAR ¼ endovascular aortic repair; AMI ¼ acute myocardial infarction; TIA ¼ transient ischemic attack.
a Primary (combined) endpoint including mortality, acute myocardial infarction (AMI), stroke, amputation, bowel ischemia, renal failure.
b Multivariate regression adjusted for screening-detection, method of intervention (OR and EVAR), age (<68, 68).
Outcome after Surgery on Screening-Detected AAA’s 653Multivariate logistic regression (Table 6) shows an
increased risk of death at 90 days for non-screening-
detected patients (OR 3.31, 95% CI, 1.05e10.46) when
adjusted for age and method of intervention (EVAR or OR).
VALIDITY OF SCREENING VARIABLE
Validation of 100 patients’ screening data showed that four
(n ¼ 4) patients were registered as having a population-
based screening-detected aneurysm when it was not and
one patient was registered as having a non-screening-
detected aneurysm when it was screening-detected. Thus,
there was a 95% match when comparing a true population-
based screening ﬁnding of AAA with the variable, “screening
detected”, in Swedvasc.
DISCUSSION
The most important ﬁnding of this contemporary
population-based study of AAAs is the overall low post-
operative morbidity and mortality in this cohort ofTable 4. Mortality in screening-detected AAA patients compared
with all non-screening-detected AAA patients.
Mortality
after surgery
Screening-
detected n (%)
Non screening-
detected
all ages n (%)
p
n ¼ 350 n ¼ 1606
30-day mortality 2/350 (0.6) 26/1606 (1.6) .21
90-day mortality 4/350 (1.1) 46/1606 (2.9) .09
1-year mortality 9/313 (2.9) 83/1460 (5.7) .048screening-detected patients and controls. Between
screening-detected patients and non-screening-detected
controls no difference in comorbidity, 30-day mortality, 1-
year mortality, or major adverse events was found. The
90-day mortality was lower for the screening-detected
patients.
The lower 90-day mortality among the screening-
detected men, compared to the age-matched controls in-
dicates a lower surgical risk, but caution in the interpreta-
tion is warranted due to the higher age of the controls.
Although some adjustment for the age difference was done
in the regression analysis it is not possible to conclude a
lower mortality in the screened cohort. The data should be
interpreted carefully since the low number of events
probably made the study underpowered to give a conclu-
sive answer regarding differences between patients with
screening-detected and non-screening-detected aneurysms.
The presence of a type II error cannot be excluded. Despite
this, the data are important since the window of opportu-
nity to conduct this study will be closed within a few years,
when very few non-screening-detected men of this age
group will be available for comparison.
When comparing short-term mortality after AAA surgery
with that in other studies, the EVAR/OR rate needs to be
considered, since EVAR has a lower short-term mortality. A
report from the United Kingdom, with a proportion of
EVARs similar to that in this cohort (45%), has shown a
correspondingly low 30-day mortality for their screening-
detected AAAs (UK, 1.6%; Sweden, 0.6%).31 Another
Table 5. Mortality after Open Repair and EndoVascular Aortic Repair (EVAR) in screening-detected AAA patients compared to non-
screening-detected age-matched controls.
Mortality Open repair (n ¼ 352) EVAR (n ¼ 348) All (n ¼ 700)
Screening-
detected,
n (%)
Non screening-
detected,
n (%)
p Screening
detected,
n (%)
Non screening-
detected,
n (%)
p Screening
detected,
n (%)
Non screening-
detected,
n (%)
p
n 195 157 155 193 350 350
30-day 2/195 (1.0) 5/157 (3.2) 0.25 0/155 (0) 0/193 (0) 2/350 (0.6) 5/350 (1.4) 0.45
90-day 4/195 (2.1) 7/157 (4.5) 0.23 0/155 (0) 6/193 (3.1) 0.04 4/350 (1.1) 13/350 (3.7) 0.046
1-year 7/173 (4.0) 9/155 (5.8) 0.61 2/140 (1.4) 9/191 (4.7) 0.13 9/313 (2.9) 18/346 (5.2) 0.17
AAA ¼ abdominal aortic aneurysm.
654 A. Linné et al.contemporary comparison could be made with the ran-
domized ACE trial which also had a low 30-day mortality
after OR and EVAR (0.6% and 1.3%).21 Both groups in this
current study are younger than any average AAA cohort,
which contributes to the low mortality. The recently re-
ported low 30-day mortality in this study and the above
mentioned probably reﬂects the relatively young cohorts
and an increasing rate of EVAR, but it could also be an effect
of centralized surgery, improved peri-operative care, and
less comorbidity.
Before AAA screening started, almost all electively treated
AAAs were detected coincidentally, in patients who had
sought medical advice for a symptom, and were therefore
more likely to have a coexisting disease. In theory, it is likely
that screening-detected patients would have fewer coexist-
ing diseases. Importantly, the anticipated differences in pre-
existing comorbidities between the screening-detected and
the age-matched non-screening-detected group were not
found. This may also be the reason that signiﬁcantTable 6. Odds ratio (OR) of death at 90 days after surgery. Univariate
missing data).
Frequency and risk of death 90-day mortality, n (%)
n ¼ 699
All 17 (2.4)
Screening-detected 4 (1.1)
Non-screening-detected (missing ¼ 0) 13 (3.7)
Open Repair 11 (3.1)
EVAR (missing ¼ 0) 6 (1.7)
Age <68 years 6 (1.7)
Age 68 years (missing ¼ 0) 11 (3.1)
Hypertension, No 3 (1.9)
Hypertension, Yes (missing ¼ 46) 13 (2.6)
Diabetes, No 14 (2.4)
Diabetes, Yes (missing ¼ 43) 2 (2.5)
Creatinine < 150 15 (2.2)
Creatinine > 150 (missing ¼ 0) 2 (9.5)
Ever-smokerb 12 (2.3)
Never-smoker (missing ¼ 112) 0
Previous heart cond, No 6 (1.6)
Previous heart cond, Yes (missing 46) 9 (3.4)
Respiratory disease, No 9 (1.8)
Respiratory disease, Yes (missing ¼ 54) 7 (5.2)
Previous TIA/stroke, No 13 (2.3)
Previous TIA/stroke, Yes (missing ¼ 46) 3 (3.4)
a Multivariate regression adjusted for screening detection, age and me
b Current or previous smoker.differences in outcomes (except for 90-day mortality) were
not found. Despite the lack of any detected difference in
comorbidity, there is a rather large difference in the methods
chosen for aneurysm repair. Screening-detected patients
have been treated with open repair in 56% of cases,
compared to 45% in the non-screening-detected cases. This
may possibly reﬂect a preconceived notion that screening-
detected patients are healthier than others and would
tolerate open surgery better. The treating vascular surgeons
choose the method of prophylactic treatment (OR or EVAR)
and the Swedvasc registry does not include data regarding
reasons for the choice. The potential endoleak problems
when offering EVAR to young patients could also have an
impact on the decision; endoleak registration is possibly
under-reported and not validated in Swedvasc and therefore
not reported here.
In this cohort of men undergoing elective repair of an
AAA, only 18% were screening-detected. Since the
screening programs in Sweden started regionally in 2006(crude) and adjusted analyses (n ¼ 699, 1 patient excluded due to
OR death 90
days crude
CI 95% OR death
90 days adja
95% CI
n ¼ 699
17
Ref Ref
3.33 1.07e10.31 3.31 1.05e10.46
1.83 0.67e5.01 2.23 0.80e6.20
Ref Ref
Ref 0.66e4.96 Ref 0.58e4.60
1.81 1.64
1.36 0.38e4.85
Ref
1.01 0.23e4.53
Ref
4.64 0.99e21.73
Ref
2.18 0.77e6.21
Ref
3.03 1.11e8.30
Ref
1.51 0.42e5.42
thod of intervention (OR and EVAR).
Outcome after Surgery on Screening-Detected AAA’s 655and were gradually implemented, the non-screening-
detected cohort in this study probably consists mainly of
patients who have not been offered AAA screening. In
coming years there will be no cohort of non-screened like
this available in Sweden among men since screening will
ﬁnd most of the aneurysms.
The strengths of this study are that it comprises a
population-based screening cohort with nationwide
coverage and that the mortality data from the Swedish
National Board of Health and Welfare are highly accurate. It
is important data in the sense that, although AAA screening
is becoming more common in the Western world, results
from surgery after screening are sparse. Also, recent data
show that AAA disease is not declining globally and will
require further improvements in care.32 The population-
based design of this study, with a considerable variety in
the size of contributing hospitals, renders a good external
validity of the results. The risk of misclassiﬁcation of
comorbidities exists in a registry but is probably low. If
present, it is believed that it is non-differential and not
related to if the patient is screening-detected or not. This
means that limited misclassiﬁcation of comorbidities would
not affect the results in any substantial way.
This study is limited by some factors. Firstly, the data are
registry based, but Swedvasc has been validated with
excellent results for AAA surgery on several occasions and
the screening variable has been validated separately in the
present study. All available data regarding screening-
detected men have been analyzed, but a type 2 error
cannot be excluded when comparing mortality and major
adverse events between the two groups, due to the small
number of patients with poor outcome. A 2-year span in the
random selection of age-matched controls was allowed
because of the low frequency of patients aged <67 years.
This resulted in a slightly older group of non-screening
detected AAA patients, which may have affected results,
and comparisons between the two groups should be
interpreted with caution. Although favorable, the good
outcome of aortic surgery provides us with few events to
analyze confounders related to mortality and post-operative
complications. Also, the use of a combined endpoint, as
previously described by others, did not result in any dif-
ference between the groups.21,26
In conclusion, post-operative mortality after AAA surgery
was low in this contemporary national audit of patients with
screening-detected aneurysms and age-matched controls.
Patients with screening-detected aneurysms have the same
comorbidities and outcome as non-screening-detected age-
matched controls, except for 90-day mortality after EVAR,
which is lower. It is safe to offer either open or endovascular
treatment in this young cohort. Our data lends further
support to national screening programs for AAA.
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